Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Innovations in Breast Cancer Surgery: Advancing Treatment Paradigms
share announcement

Innovations in Breast Cancer Surgery: Advancing Treatment Paradigms

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 6 November 2024 | Viewed by 733

Special Issue Editor

Prof. Dr. Kefah Mokbel

E-Mail Website
Guest Editor
The London Breast Institute, Princess Grace Hospital, 42-52 Nottingham Place, London W1U 5NY, UK
Interests: breast cancer; stem cells; gene profiling; autophagy; liquid biopsy; microRNA
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Journal of Clinical Medicine is thrilled to announce a Special Issue dedicated to the latest developments in the surgical treatment of breast cancer. We invite authors to submit original research and review articles shedding light on innovative oncoplastic surgical techniques, advancements in reconstructive surgery, robotic nipple sparing mastectomy, deescalation of breast cancer surgery strategies such as targeted axillary dissection, and wire-free localisation techniques for non-palpable breast and axillary lesions.

This Special Issue aims to provide a comprehensive overview of the evolving landscape of surgical interventions for breast cancer, including minimally invasive procedures, novel biomaterials, and emerging technologies.

Authors are invited to submit their manuscripts through the journal's online submission system. Submissions will undergo a rigorous peer review process to ensure the highest quality and relevance to our readership. Do not miss this opportunity to contribute to the advancement of breast cancer surgery and submit your work to the Journal of Clinical Medicine's Special Issue today!

Prof. Dr. Kefah Mokbel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • reconstructive surgery
  • robotic nipple sparring mastectomy 
  • minimally invasive surgery
  • oncoplastic breast surgery
  • wire-free breast localisation
  • de-escalation of breast cancer surgery 

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

15 pages, 2898 KiB  
Systematic Review
Evaluating Magnetic Seed Localization in Targeted Axillary Dissection for Node-Positive Early Breast Cancer Patients Receiving Neoadjuvant Systemic Therapy: A Comprehensive Review and Pooled Analysis
by Munaser Alamoodi, Umar Wazir, Rita A. Sakr, Janhavi Venkataraman, Kinan Mokbel and Kefah Mokbel
J. Clin. Med. 2024, 13(10), 2908; https://doi.org/10.3390/jcm13102908 - 14 May 2024
Viewed by 528
Abstract
Background/Objectives: De-escalation of axillary surgery is made possible by advancements in both neoadjuvant systemic therapy (NST) and in localisation technology for breast lesions. Magseed®, developed in 2013 by Dr. Michael Douk of Cambridge, United Kingdom, is a wire-free localisation technology that [...] Read more.
Background/Objectives: De-escalation of axillary surgery is made possible by advancements in both neoadjuvant systemic therapy (NST) and in localisation technology for breast lesions. Magseed®, developed in 2013 by Dr. Michael Douk of Cambridge, United Kingdom, is a wire-free localisation technology that facilitates the localisation and retrieval of lymph nodes for staging. Targeted axillary dissection (TAD), which entails marked lymph node biopsy (MLNB) and sentinel lymph node biopsy (SLNB), has emerged as the preferred method to assess residual disease in post-NST node-positive patients. This systematic review and pooled analysis evaluate the performance of Magseed® in TAD. Methods: The search was carried out in PubMed and Google Scholar. An assessment of localisation, retrieval rates, concordance between MLNB and SLNB, and pathological complete response (pCR) in clinically node-positive patients post NST was undertaken. Results: Nine studies spanning 494 patients and 497 procedures were identified, with a 100% successful deployment rate, a 94.2% (468/497) [95% confidence interval (CI), 93.7–94.7] localisation rate, a 98.8% (491/497) retrieval rate, and a 68.8% (247/359) [95% CI 65.6–72.0] concordance rate. pCR was observed in 47.9% (220/459) ) [95% CI 43.3–52.6] of cases. Subgroup analysis of studies reporting the pathological status of MLNB and SLNB separately revealed an FNR of 4.2% for MLNB and 17.6% for SLNB (p = 0.0013). Mean duration of implantation was 37 days (range: 0–188). Conclusions: These findings highlight magnetic seed localisation’s efficacy in TAD for NST-treated node-positive patients, aiding in accurate axillary pCR identification and safe de-escalation of axillary surgery in excellent responders. Full article
(This article belongs to the Special Issue Innovations in Breast Cancer Surgery: Advancing Treatment Paradigms)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop